Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Fineline Cube Jan 30, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Drug

RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval

Fineline Cube Mar 6, 2025

China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...

Company Deals

Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies

Fineline Cube Mar 6, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...

Company Deals

Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs

Fineline Cube Mar 6, 2025

China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...

Company Deals

Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China

Fineline Cube Mar 6, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...

Company Drug

Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study

Fineline Cube Mar 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...

Company Deals

CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...

Company Drug

Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial

Fineline Cube Mar 6, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...

Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Company

MSD China Reorganizes to Boost Mature Product Lines

Fineline Cube Mar 5, 2025

Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...

Company Drug

Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE

Fineline Cube Mar 5, 2025

China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...

Policy / Regulatory

CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D

Fineline Cube Mar 5, 2025

China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment

Fineline Cube Mar 5, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...

Company

Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars

Fineline Cube Mar 4, 2025

Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study

Fineline Cube Mar 4, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...

Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Posts pagination

1 … 152 153 154 … 616

Recent updates

  • Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
  • Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
  • Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
  • CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
  • Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.